Lignocaine infusion to reduce propofol consumption in laparoscopic cholecystectomy

A randomized controlled study to evaluate the effect of intraoperative lignocaine infusion on propofol consumption during laparoscopic cholecystectomy - LIRPOL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042101

Enrollment

Registered

2020-10-31

Start date

2019-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative period

Interventions

Lignocaine drug infusion in perioperative period Placebo(Normal saline) infusion in perioperative period

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consenting adults undergoing laparoscopic cholecystectomy ASA-1 and 2

Exclusion criteria

Exclusion criteria: 1. Age < 18 years and > 65 years. 2. Patients not willing to participate in this study. 3. Emergency surgeries. 4. Morbid obesity or BMI>35 5. History of allergy to local anaesthetic agents. 6. History of chronic smoking. 7. Use of opioids or anti-arrhythmic drugs within 1 week of surgery. 8. Cardiorespiratory abnormalities NYHA class 3 and 4, severe COPD. 9. Liver dysfunction (bilirubin and liver enzymes values elevated by 50% of normal 10.Renal insufficiency (serum creatinine >1.6mg/dl) 11.Epilepsy or other neurological diseases

Design outcomes

Primary

Measure	Time frame
To assess whether intravenous lignocaine reduces propofol consumption during laparoscopic cholecystectomy using TCI (Target Controlled Infusion)	—

Secondary

Measure	Time frame
Effect of lignocaine infusion on hemodynamic parameters	—

Countries

Asia(except Japan)

Contacts

Public ContactSwetha Chandrashekarappa

Manipal Hospitals Anaesthesiology

swethasantosh9@gmail.com959481909899

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026